OncoMatch/Clinical Trials/NCT07736937
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
Is NCT07736937 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies TUB-040 + Carbo + BEV for ovarian cancer.
Treatment: TUB-040 + Carbo + BEV — The goal of this clinical study is to learn more about the safety, tolerability, and preliminary effectiveness of TUB-040 when given in combination with standard ovarian cancer treatments in participants with high-grade epithelial serous or endometrioid ovarian cancer. This study will also evaluate the appropriate dose of TUB-040 when used with carboplatin (Carbo) and bevacizumab (BEV), including determining the maximum tolerated dose (MTD) in participants with platinum-sensitive ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Disease stage
Grade: high-grade
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic platinum therapy
Patients must have 1-2 prior lines of systemic platinum therapy and have not progressed within 182 days after the date of the last dose of platinum.
Cannot have received: PARP inhibitor
Exception: required only for patients previously documented to be HRD positive or have a germline or somatic BRCA1/2 mutation, if PARPi therapy was locally approved at the time of testing
Prior treatment with PARPi is required (for patients who were previously documented to be HRD positive or have a germline or somatic BRCA 1/2 mutation), if PARPi therapy was locally approved at the time of testing.
Cannot have received: systemic topoisomerase 1 inhibitor
Exception: except Topotecan
Previous systemic topoisomerase-1 inhibitor treatment (except Topotecan)
Lab requirements
Blood counts
Platelet counts ≥100,000/mm3 (no transfusion/growth factors within 4 weeks); Hemoglobin ≥9.0 g/dL (no transfusion/growth factors within 4 weeks); ANC ≥1500/μL (no growth factors within 4 weeks); INR ≤1.5 and aPTT ≤1.5 × ULN (unless on anticoagulation, then INR in therapeutic range)
Kidney function
glomerular filtration rate ≥60 mL/min (CKD-EPI)
Liver function
total bilirubin ≤1.5 × ULN (Gilbert's: <3 × ULN accepted); AST/ALT ≤2.5 × ULN (liver mets: <5 × ULN accepted)
Adequate hematologic function as indicated by: Platelet counts ≥100,000/mm3... Hemoglobin ≥9.0 g/dL... ANC ≥1500/μL... INR ≤1.5 and aPTT ≤1.5 × ULN... Adequate hepatic function defined as total bilirubin level ≤1.5 × ULN... AST/ALT ≤2.5 × ULN... For documented Gilbert's Syndrome, a total bilirubin <3 × ULN is accepted... For patients with liver metastases, AST and ALT <5 × ULN is accepted... Adequate renal function defined by glomerular filtration rate ≥60 mL/min (CKD-EPI)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07736937 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PARP inhibitor, systemic topoisomerase 1 inhibitor disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages